Clinical trial
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or…
NCT00087009 · Memorial Sloan Kettering Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00087009 |
|---|---|
| Title | Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation |
| Official title | Phase I Study of Oral ß-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Lymphoproliferative Disorder |
| Intervention type | Biological |
| Interventions | beta-glucan, rituximab |
| Enrollment | 3 |
| Start date | May 1, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jul 12, 2004 |
| Last update posted | Mar 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: